The Lung Cancer Drug That Works After Everything Else Stops
BridgeBio's BBO-8520 is showing striking early response rates in lung cancer patients who've already failed KRAS G12C inhibitors. In a space with no approved salvage therapy, even preliminary data from this dual-mechanism drug has oncologists and Wall Street leaning in.
A Second Chance Nobody Expected
Imagine you're fighting a fire with the best extinguisher money can buy. It works for a while, then the flames figure out how to reignite. Now imagine someone hands you a new extinguisher that attacks the fire from two directions at once. That's roughly the story of BBO-8520.
BridgeBio just dropped updated clinical data for its experimental drug BBO-8520, and the numbers are turning heads. In combination with Merck's pembrolizumab (the blockbuster immunotherapy sold as Keytruda), BBO-8520 posted a 75% response rate at the 500mg dose in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) who had already failed prior KRAS G12C inhibitors. These are patients who, by definition, had run out of good options.
For context, once a lung cancer patient's tumor outsmarts a KRAS G12C inhibitor like sotorasib or adagrasib, the typical next move is old-school chemotherapy. There is no approved targeted salvage therapy waiting in the wings. Which is what makes this data feel like a lifeline.
Why KRAS G12C Is Such a Stubborn Target
KRAS mutations have been called "undruggable" for decades. They're like a light switch stuck in the "on" position, constantly telling cancer cells to grow. The first generation of KRAS G12C inhibitors (sotorasib and adagrasib) finally cracked the code by grabbing onto the protein when it's switched off, in what scientists call the GDP-bound or "inactive" state.
The problem? Cancer adapts. Tumors develop resistance through several escape routes: secondary mutations in the KRAS gene itself (especially tricky variants like Y96D), activation of bypass pathways through EGFR or PI3K signaling, and even full-blown cellular identity changes like epithelial-to-mesenchymal transition. Think of it like a prison break where the inmates don't just find one tunnel; they dig several at once.
Once resistance kicks in, switching from sotorasib to adagrasib (or vice versa) usually doesn't help much. Both drugs grab the same pocket on the protein, so mutations that block one tend to block the other too.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
This is where BBO-8520 gets interesting. Unlike first-generation drugs that only work when KRAS is in its "off" position, BBO-8520 is a dual inhibitor that locks onto KRAS G12C in both its active (GTP-bound, "on") and inactive (GDP-bound, "off") states.
Picture it this way: the old drugs could only tackle you when you were sitting down. BBO-8520 can tackle you whether you're sitting or standing. It binds to something called the Switch-II/Helix 3 pocket and jams KRAS into a shape that can't signal to downstream partners like RAF1. The result, at least in preclinical models, is durable tumor shrinkage even in cancers that had already beaten first-gen KRAS G12C inhibitors.
BridgeBio developed the drug in collaboration with the NCI RAS Initiative and Lawrence Livermore National Laboratory. The FDA cleared its investigational new drug application in January 2024.
The Data So Far: Small but Striking
BBO-8520 is still in Phase 1 testing (the ONKORAS-101 trial), so we're talking about early-stage safety and dose-finding data, not the kind of large, randomized results that get drugs approved. But the early signals are hard to ignore.
Across all BBO-8520 doses as monotherapy in NSCLC, investigators reported a 65% overall response rate (11 out of 17 patients), including one complete response and ten partial responses. Every single efficacy-evaluable patient (all eight) in the pembrolizumab combination cohort saw their tumors shrink.
Breaking down the combo arm further: three out of three front-line patients achieved partial responses, and two out of five patients previously treated with a KRAS G12C inhibitor also responded. Those numbers are tiny, and the 75% figure at 500mg in KRAS G12C inhibitor-experienced patients comes from the company's latest update.
Small patient counts demand a healthy dose of skepticism. A single additional responder (or non-responder) can swing these percentages wildly. But in a population where the alternative is essentially chemotherapy, even preliminary signals carry weight.
Wall Street Is Paying Attention
The financial world has noticed. Stifel initiated coverage of BridgeBio Oncology with a Buy rating and a $23 price target. Leerink raised its target to $32, while Raymond James started coverage at Outperform with a $24 target. The common thread across all three: the differentiated mechanism and early efficacy are worth betting on, even at this stage.
BridgeBio itself has signaled that the second-line-plus NSCLC combo with pembrolizumab is now a strategic priority. The company promised additional combination efficacy and safety data in the second half of 2026, which means we should see a fuller picture soon.
The Bigger Picture: Rewriting the Playbook
Right now, the standard treatment sequence for KRAS G12C lung cancer looks something like this: start with chemoimmunotherapy, move to a KRAS G12C inhibitor at progression, then fall back to chemotherapy when that stops working. It's a three-step ladder with a disappointing bottom rung.
If BBO-8520 plus pembrolizumab holds up in larger trials, it could add a meaningful fourth step, or even reshuffle the whole order. A targeted salvage option for post-KRAS-inhibitor patients would fill a gap that oncologists have been complaining about since sotorasib first hit the market.
The competitive landscape is getting crowded, too. Next-generation KRAS G12C agents like divarasib and olomorasib are also in clinical development, along with combination strategies involving SHP2, MEK, and SOS1 inhibitors. But BBO-8520's dual ON/OFF mechanism gives it a distinct angle that most competitors don't share.
What to Watch
Three things will determine whether BBO-8520 becomes a real player or just another promising early-phase story:
Durability of response. Shrinking tumors is great; keeping them small is what matters. We need longer follow-up to see how long these responses last.
Safety at the 500mg dose. Phase 1 tolerability has looked manageable so far, but combining a novel agent with pembrolizumab always raises the stakes for immune-related and overlapping toxicities.
Larger patient numbers. Moving from single-digit cohorts to expansion-stage data will tell us whether 75% is real or a statistical mirage from tiny sample sizes.
BridgeBio has said more data is coming later this year. For the thousands of lung cancer patients whose tumors have already outsmarted the first wave of KRAS drugs, the wait matters more than most.
Clinical & Regulatory4 min read
Roivant's Lung Drug Just Posted Data That Has Wall Street Buzzing
Roivant's inhaled lung drug just posted Phase 2 data strong enough to send the stock up 20% in a day. One analyst thinks it could be a $10 billion-a-year drug. Here's why the numbers have Wall Street losing its mind.
